Clinical Trial Update: Azacitidine With or Without Ceplene/Interleukin-2 in Patients With Higher Risk Myelodysplastic Syndromes [Phase 1, Phase 2]

View source ↗

Summary

A Phase 1/2 trial investigating azacitidine with or without Ceplene (histamine dihydrochloride) and interleukin-2 for higher-risk myelodysplastic syndromes has …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Myelodysplastic Syndromes

Drugs mentioned

• AZACITIDINE (AZACITIDINE)
• Ceplene (histamine dihydrochloride)
• Interleukin-2 (interleukin-2)

Snippet

Sponsor: Groupe Francophone des Myelodysplasies | Conditions: Myelodysplastic Syndromes | Phase 1, Phase 2 | Status: WITHDRAWN